▶ 調査レポート

世界の伝染性コリーザワクチン市場インサイト・予測(~2027年)

• 英文タイトル:Global Infectious Coryza Vaccine Market Insights and Forecast to 2027

QYResearchが調査・発行した産業分析レポートです。世界の伝染性コリーザワクチン市場インサイト・予測(~2027年) / Global Infectious Coryza Vaccine Market Insights and Forecast to 2027 / QY2108PAL3978資料のイメージです。• レポートコード:QY2108PAL3978
• 出版社/出版日:QYResearch / 2021年8月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、111ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥735,000 (USD4,900)▷ お問い合わせ
  Multi User¥1,102,500 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,470,000 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査資料は伝染性コリーザワクチンの世界市場の現状について調査・分析し、2027年までの市場を予測しました。伝染性コリーザワクチンの世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模(一価ワクチン、二価ワクチン、三価ワクチン)、用途別市場規模(小売、オンライン販売、その他)、主要地域別市場規模(北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ)、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。

・伝染性コリーザワクチンの世界市場概要
・メーカー別の競争状況、市場シェア
・伝染性コリーザワクチンの種類別市場規模:一価ワクチン、二価ワクチン、三価ワクチン
・伝染性コリーザワクチンの用途別市場規模:小売、オンライン販売、その他
・北米の伝染性コリーザワクチン市場規模2016-2027:種類別、用途別、国別(アメリカ、カナダ)
・ヨーロッパの伝染性コリーザワクチン市場規模2016-2027:種類別、用途別、国別(ドイツ、フランス、イギリス)
・アジアの伝染性コリーザワクチン市場規模2016-2027:種類別、用途別、国別(日本、中国、インド、韓国)
・中南米の伝染性コリーザワクチン市場規模2016-2027:種類別、用途別、国別(メキシコ、ブラジル)
・中東・アフリカの伝染性コリーザワクチン市場規模2016-2027:種類別、用途別、国別(トルコ、サウジアラビア)
・企業情報:Zoetis、Merck、Boehringer Ingelheim、Ceva Santé Animale、Qilu Animal Health Products Co., Ltd.、Tianjin Ruipu Biotechnology Co., Ltd.、Harbin Pharmaceutical Group、Plyco Bioengineering Co., Ltd.、Qingdao Yibang Biological Engineering Co., Ltd.、Shandong Lvdu Biological Technology Co., Ltd.、Shandong Huahong Biological Engineering Co., Ltd.
・伝染性コリーザワクチンのバリューチェーン・販売チャネル分析
・伝染性コリーザワクチンの世界市場動向

Infectious Coryza Vaccine is used to prevent infectious rhinitis in chickens caused by Avian bacillus paragallinarum. The method is subcutaneous injection on the back of the neck.

Market Analysis and Insights: Global Infectious Coryza Vaccine Market
The global Infectious Coryza Vaccine market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.

Global Infectious Coryza Vaccine Scope and Segment
Infectious Coryza Vaccine market is segmented by Type, and by Distribution Channel. Players, stakeholders, and other participants in the global Infectious Coryza Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Distribution Channel for the period 2016-2027.

Segment by Type
Monovalent Vaccine
Bivalent Vaccine
Trivalent Vaccine

Segment by Distribution Channel
Retail
Online Sale
Others

By Company
Zoetis
Merck
Boehringer Ingelheim
Ceva Santé Animale
Qilu Animal Health Products Co., Ltd.
Tianjin Ruipu Biotechnology Co., Ltd.
Harbin Pharmaceutical Group
Plyco Bioengineering Co., Ltd.
Qingdao Yibang Biological Engineering Co., Ltd.
Shandong Lvdu Biological Technology Co., Ltd.
Shandong Huahong Biological Engineering Co., Ltd.

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

1 Study Coverage
1.1 Infectious Coryza Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Infectious Coryza Vaccine Market Size Growth Rate by Type
1.2.2 Monovalent Vaccine
1.2.3 Bivalent Vaccine
1.2.4 Trivalent Vaccine
1.3 Market by Distribution Channel
1.3.1 Global Infectious Coryza Vaccine Market Size Growth Rate by Distribution Channel
1.3.2 Retail
1.3.3 Online Sale
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Infectious Coryza Vaccine Sales Estimates and Forecasts 2016-2027
2.2 Global Infectious Coryza Vaccine Revenue Estimates and Forecasts 2016-2027
2.3 Global Infectious Coryza Vaccine Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Infectious Coryza Vaccine Regions by Sales
2.4.1 Global Top Infectious Coryza Vaccine Regions by Sales (2016-2021)
2.4.2 Global Top Infectious Coryza Vaccine Regions by Sales (2022-2027)
2.5 Global Top Infectious Coryza Vaccine Regions by Revenue
2.5.1 Global Top Infectious Coryza Vaccine Regions by Revenue (2016-2021)
2.5.2 Global Top Infectious Coryza Vaccine Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Infectious Coryza Vaccine Sales by Manufacturers
3.1.1 Global Top Infectious Coryza Vaccine Manufacturers by Sales (2016-2021)
3.1.2 Global Top Infectious Coryza Vaccine Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Infectious Coryza Vaccine Sales in 2020
3.2 Global Infectious Coryza Vaccine Revenue by Manufacturers
3.2.1 Global Top Infectious Coryza Vaccine Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Infectious Coryza Vaccine Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Infectious Coryza Vaccine Revenue in 2020
3.3 Global Infectious Coryza Vaccine Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Infectious Coryza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Infectious Coryza Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Infectious Coryza Vaccine Sales by Type
4.1.1 Global Infectious Coryza Vaccine Historical Sales by Type (2016-2021)
4.1.2 Global Infectious Coryza Vaccine Forecasted Sales by Type (2022-2027)
4.1.3 Global Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
4.2 Global Infectious Coryza Vaccine Revenue by Type
4.2.1 Global Infectious Coryza Vaccine Historical Revenue by Type (2016-2021)
4.2.2 Global Infectious Coryza Vaccine Forecasted Revenue by Type (2022-2027)
4.2.3 Global Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
4.3 Global Infectious Coryza Vaccine Price by Type
4.3.1 Global Infectious Coryza Vaccine Price by Type (2016-2021)
4.3.2 Global Infectious Coryza Vaccine Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Infectious Coryza Vaccine Sales by Distribution Channel
5.1.1 Global Infectious Coryza Vaccine Historical Sales by Distribution Channel (2016-2021)
5.1.2 Global Infectious Coryza Vaccine Forecasted Sales by Distribution Channel (2022-2027)
5.1.3 Global Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
5.2 Global Infectious Coryza Vaccine Revenue by Distribution Channel
5.2.1 Global Infectious Coryza Vaccine Historical Revenue by Distribution Channel (2016-2021)
5.2.2 Global Infectious Coryza Vaccine Forecasted Revenue by Distribution Channel (2022-2027)
5.2.3 Global Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
5.3 Global Infectious Coryza Vaccine Price by Distribution Channel
5.3.1 Global Infectious Coryza Vaccine Price by Distribution Channel (2016-2021)
5.3.2 Global Infectious Coryza Vaccine Price Forecast by Distribution Channel (2022-2027)

6 North America
6.1 North America Infectious Coryza Vaccine Market Size by Type
6.1.1 North America Infectious Coryza Vaccine Sales by Type (2016-2027)
6.1.2 North America Infectious Coryza Vaccine Revenue by Type (2016-2027)
6.2 North America Infectious Coryza Vaccine Market Size by Distribution Channel
6.2.1 North America Infectious Coryza Vaccine Sales by Distribution Channel (2016-2027)
6.2.2 North America Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2027)
6.3 North America Infectious Coryza Vaccine Market Size by Country
6.3.1 North America Infectious Coryza Vaccine Sales by Country (2016-2027)
6.3.2 North America Infectious Coryza Vaccine Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Infectious Coryza Vaccine Market Size by Type
7.1.1 Europe Infectious Coryza Vaccine Sales by Type (2016-2027)
7.1.2 Europe Infectious Coryza Vaccine Revenue by Type (2016-2027)
7.2 Europe Infectious Coryza Vaccine Market Size by Distribution Channel
7.2.1 Europe Infectious Coryza Vaccine Sales by Distribution Channel (2016-2027)
7.2.2 Europe Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2027)
7.3 Europe Infectious Coryza Vaccine Market Size by Country
7.3.1 Europe Infectious Coryza Vaccine Sales by Country (2016-2027)
7.3.2 Europe Infectious Coryza Vaccine Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Infectious Coryza Vaccine Market Size by Type
8.1.1 Asia Pacific Infectious Coryza Vaccine Sales by Type (2016-2027)
8.1.2 Asia Pacific Infectious Coryza Vaccine Revenue by Type (2016-2027)
8.2 Asia Pacific Infectious Coryza Vaccine Market Size by Distribution Channel
8.2.1 Asia Pacific Infectious Coryza Vaccine Sales by Distribution Channel (2016-2027)
8.2.2 Asia Pacific Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2027)
8.3 Asia Pacific Infectious Coryza Vaccine Market Size by Region
8.3.1 Asia Pacific Infectious Coryza Vaccine Sales by Region (2016-2027)
8.3.2 Asia Pacific Infectious Coryza Vaccine Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Infectious Coryza Vaccine Market Size by Type
9.1.1 Latin America Infectious Coryza Vaccine Sales by Type (2016-2027)
9.1.2 Latin America Infectious Coryza Vaccine Revenue by Type (2016-2027)
9.2 Latin America Infectious Coryza Vaccine Market Size by Distribution Channel
9.2.1 Latin America Infectious Coryza Vaccine Sales by Distribution Channel (2016-2027)
9.2.2 Latin America Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2027)
9.3 Latin America Infectious Coryza Vaccine Market Size by Country
9.3.1 Latin America Infectious Coryza Vaccine Sales by Country (2016-2027)
9.3.2 Latin America Infectious Coryza Vaccine Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Infectious Coryza Vaccine Market Size by Type
10.1.1 Middle East and Africa Infectious Coryza Vaccine Sales by Type (2016-2027)
10.1.2 Middle East and Africa Infectious Coryza Vaccine Revenue by Type (2016-2027)
10.2 Middle East and Africa Infectious Coryza Vaccine Market Size by Distribution Channel
10.2.1 Middle East and Africa Infectious Coryza Vaccine Sales by Distribution Channel (2016-2027)
10.2.2 Middle East and Africa Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2027)
10.3 Middle East and Africa Infectious Coryza Vaccine Market Size by Country
10.3.1 Middle East and Africa Infectious Coryza Vaccine Sales by Country (2016-2027)
10.3.2 Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Zoetis
11.1.1 Zoetis Corporation Information
11.1.2 Zoetis Overview
11.1.3 Zoetis Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Zoetis Infectious Coryza Vaccine Product Description
11.1.5 Zoetis Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Merck Infectious Coryza Vaccine Product Description
11.2.5 Merck Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Boehringer Ingelheim Infectious Coryza Vaccine Product Description
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Overview
11.4.3 Ceva Santé Animale Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Ceva Santé Animale Infectious Coryza Vaccine Product Description
11.4.5 Ceva Santé Animale Recent Developments
11.5 Qilu Animal Health Products Co., Ltd.
11.5.1 Qilu Animal Health Products Co., Ltd. Corporation Information
11.5.2 Qilu Animal Health Products Co., Ltd. Overview
11.5.3 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product Description
11.5.5 Qilu Animal Health Products Co., Ltd. Recent Developments
11.6 Tianjin Ruipu Biotechnology Co., Ltd.
11.6.1 Tianjin Ruipu Biotechnology Co., Ltd. Corporation Information
11.6.2 Tianjin Ruipu Biotechnology Co., Ltd. Overview
11.6.3 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product Description
11.6.5 Tianjin Ruipu Biotechnology Co., Ltd. Recent Developments
11.7 Harbin Pharmaceutical Group
11.7.1 Harbin Pharmaceutical Group Corporation Information
11.7.2 Harbin Pharmaceutical Group Overview
11.7.3 Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Harbin Pharmaceutical Group Infectious Coryza Vaccine Product Description
11.7.5 Harbin Pharmaceutical Group Recent Developments
11.8 Plyco Bioengineering Co., Ltd.
11.8.1 Plyco Bioengineering Co., Ltd. Corporation Information
11.8.2 Plyco Bioengineering Co., Ltd. Overview
11.8.3 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product Description
11.8.5 Plyco Bioengineering Co., Ltd. Recent Developments
11.9 Qingdao Yibang Biological Engineering Co., Ltd.
11.9.1 Qingdao Yibang Biological Engineering Co., Ltd. Corporation Information
11.9.2 Qingdao Yibang Biological Engineering Co., Ltd. Overview
11.9.3 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Description
11.9.5 Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments
11.10 Shandong Lvdu Biological Technology Co., Ltd.
11.10.1 Shandong Lvdu Biological Technology Co., Ltd. Corporation Information
11.10.2 Shandong Lvdu Biological Technology Co., Ltd. Overview
11.10.3 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product Description
11.10.5 Shandong Lvdu Biological Technology Co., Ltd. Recent Developments
11.11 Shandong Huahong Biological Engineering Co., Ltd.
11.11.1 Shandong Huahong Biological Engineering Co., Ltd. Corporation Information
11.11.2 Shandong Huahong Biological Engineering Co., Ltd. Overview
11.11.3 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Price, Revenue and Gross Margin (2016-2021)
11.11.4 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Description
11.11.5 Shandong Huahong Biological Engineering Co., Ltd. Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Infectious Coryza Vaccine Value Chain Analysis
12.2 Infectious Coryza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Infectious Coryza Vaccine Production Mode & Process
12.4 Infectious Coryza Vaccine Sales and Marketing
12.4.1 Infectious Coryza Vaccine Sales Channels
12.4.2 Infectious Coryza Vaccine Distributors
12.5 Infectious Coryza Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Infectious Coryza Vaccine Industry Trends
13.2 Infectious Coryza Vaccine Market Drivers
13.3 Infectious Coryza Vaccine Market Challenges
13.4 Infectious Coryza Vaccine Market Restraints

14 Key Findings in The Global Infectious Coryza Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Infectious Coryza Vaccine Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Monovalent Vaccine
Table 3. Major Manufacturers of Bivalent Vaccine
Table 4. Major Manufacturers of Trivalent Vaccine
Table 5. Global Infectious Coryza Vaccine Market Size Growth Rate by Distribution Channel, 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Infectious Coryza Vaccine Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 7. Global Infectious Coryza Vaccine Sales by Region (2016-2021) & (K Units)
Table 8. Global Infectious Coryza Vaccine Sales Market Share by Region (2016-2021)
Table 9. Global Infectious Coryza Vaccine Sales by Region (2022-2027) & (K Units)
Table 10. Global Infectious Coryza Vaccine Sales Market Share by Region (2022-2027)
Table 11. Global Infectious Coryza Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 12. Global Infectious Coryza Vaccine Revenue Market Share by Region (2016-2021)
Table 13. Global Infectious Coryza Vaccine Revenue by Region (2022-2027) & (US$ Million)
Table 14. Global Infectious Coryza Vaccine Revenue Market Share by Region (2022-2027)
Table 15. Global Infectious Coryza Vaccine Sales by Manufacturers (2016-2021) & (K Units)
Table 16. Global Infectious Coryza Vaccine Sales Share by Manufacturers (2016-2021)
Table 17. Global Infectious Coryza Vaccine Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 18. Global Infectious Coryza Vaccine Revenue Share by Manufacturers (2016-2021)
Table 19. Infectious Coryza Vaccine Price by Manufacturers 2016-2021 (US$/Unit)
Table 20. Global Infectious Coryza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Infectious Coryza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infectious Coryza Vaccine as of 2020)
Table 22. Infectious Coryza Vaccine Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Infectious Coryza Vaccine Product Offered
Table 24. Date of Manufacturers Enter into Infectious Coryza Vaccine Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Infectious Coryza Vaccine Sales by Type (2016-2021) & (K Units)
Table 27. Global Infectious Coryza Vaccine Sales by Type (2022-2027) & (K Units)
Table 28. Global Infectious Coryza Vaccine Sales Share by Type (2016-2021)
Table 29. Global Infectious Coryza Vaccine Sales Share by Type (2022-2027)
Table 30. Global Infectious Coryza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 31. Global Infectious Coryza Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 32. Global Infectious Coryza Vaccine Revenue Share by Type (2016-2021)
Table 33. Global Infectious Coryza Vaccine Revenue Share by Type (2022-2027)
Table 34. Infectious Coryza Vaccine Price by Type (2016-2021) & (US$/Unit)
Table 35. Global Infectious Coryza Vaccine Price Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global Infectious Coryza Vaccine Sales by Distribution Channel (2016-2021) & (K Units)
Table 37. Global Infectious Coryza Vaccine Sales by Distribution Channel (2022-2027) & (K Units)
Table 38. Global Infectious Coryza Vaccine Sales Share by Distribution Channel (2016-2021)
Table 39. Global Infectious Coryza Vaccine Sales Share by Distribution Channel (2022-2027)
Table 40. Global Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2021) & (US$ Million)
Table 41. Global Infectious Coryza Vaccine Revenue by Distribution Channel (2022-2027) & (US$ Million)
Table 42. Global Infectious Coryza Vaccine Revenue Share by Distribution Channel (2016-2021)
Table 43. Global Infectious Coryza Vaccine Revenue Share by Distribution Channel (2022-2027)
Table 44. Infectious Coryza Vaccine Price by Distribution Channel (2016-2021) & (US$/Unit)
Table 45. Global Infectious Coryza Vaccine Price Forecast by Distribution Channel (2022-2027) & (US$/Unit)
Table 46. North America Infectious Coryza Vaccine Sales by Type (2016-2021) & (K Units)
Table 47. North America Infectious Coryza Vaccine Sales by Type (2022-2027) & (K Units)
Table 48. North America Infectious Coryza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 49. North America Infectious Coryza Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 50. North America Infectious Coryza Vaccine Sales by Distribution Channel (2016-2021) & (K Units)
Table 51. North America Infectious Coryza Vaccine Sales by Distribution Channel (2022-2027) & (K Units)
Table 52. North America Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2021) & (US$ Million)
Table 53. North America Infectious Coryza Vaccine Revenue by Distribution Channel (2022-2027) & (US$ Million)
Table 54. North America Infectious Coryza Vaccine Sales by Country (2016-2021) & (K Units)
Table 55. North America Infectious Coryza Vaccine Sales by Country (2022-2027) & (K Units)
Table 56. North America Infectious Coryza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 57. North America Infectious Coryza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 58. Europe Infectious Coryza Vaccine Sales by Type (2016-2021) & (K Units)
Table 59. Europe Infectious Coryza Vaccine Sales by Type (2022-2027) & (K Units)
Table 60. Europe Infectious Coryza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 61. Europe Infectious Coryza Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 62. Europe Infectious Coryza Vaccine Sales by Distribution Channel (2016-2021) & (K Units)
Table 63. Europe Infectious Coryza Vaccine Sales by Distribution Channel (2022-2027) & (K Units)
Table 64. Europe Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2021) & (US$ Million)
Table 65. Europe Infectious Coryza Vaccine Revenue by Distribution Channel (2022-2027) & (US$ Million)
Table 66. Europe Infectious Coryza Vaccine Sales by Country (2016-2021) & (K Units)
Table 67. Europe Infectious Coryza Vaccine Sales by Country (2022-2027) & (K Units)
Table 68. Europe Infectious Coryza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 69. Europe Infectious Coryza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 70. Asia Pacific Infectious Coryza Vaccine Sales by Type (2016-2021) & (K Units)
Table 71. Asia Pacific Infectious Coryza Vaccine Sales by Type (2022-2027) & (K Units)
Table 72. Asia Pacific Infectious Coryza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 73. Asia Pacific Infectious Coryza Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 74. Asia Pacific Infectious Coryza Vaccine Sales by Distribution Channel (2016-2021) & (K Units)
Table 75. Asia Pacific Infectious Coryza Vaccine Sales by Distribution Channel (2022-2027) & (K Units)
Table 76. Asia Pacific Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2021) & (US$ Million)
Table 77. Asia Pacific Infectious Coryza Vaccine Revenue by Distribution Channel (2022-2027) & (US$ Million)
Table 78. Asia Pacific Infectious Coryza Vaccine Sales by Region (2016-2021) & (K Units)
Table 79. Asia Pacific Infectious Coryza Vaccine Sales by Region (2022-2027) & (K Units)
Table 80. Asia Pacific Infectious Coryza Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 81. Asia Pacific Infectious Coryza Vaccine Revenue by Region (2022-2027) & (US$ Million)
Table 82. Latin America Infectious Coryza Vaccine Sales by Type (2016-2021) & (K Units)
Table 83. Latin America Infectious Coryza Vaccine Sales by Type (2022-2027) & (K Units)
Table 84. Latin America Infectious Coryza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 85. Latin America Infectious Coryza Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 86. Latin America Infectious Coryza Vaccine Sales by Distribution Channel (2016-2021) & (K Units)
Table 87. Latin America Infectious Coryza Vaccine Sales by Distribution Channel (2022-2027) & (K Units)
Table 88. Latin America Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2021) & (US$ Million)
Table 89. Latin America Infectious Coryza Vaccine Revenue by Distribution Channel (2022-2027) & (US$ Million)
Table 90. Latin America Infectious Coryza Vaccine Sales by Country (2016-2021) & (K Units)
Table 91. Latin America Infectious Coryza Vaccine Sales by Country (2022-2027) & (K Units)
Table 92. Latin America Infectious Coryza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 93. Latin America Infectious Coryza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 94. Middle East and Africa Infectious Coryza Vaccine Sales by Type (2016-2021) & (K Units)
Table 95. Middle East and Africa Infectious Coryza Vaccine Sales by Type (2022-2027) & (K Units)
Table 96. Middle East and Africa Infectious Coryza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 97. Middle East and Africa Infectious Coryza Vaccine Revenue by Type (2022-2027) & (US$ Million)
Table 98. Middle East and Africa Infectious Coryza Vaccine Sales by Distribution Channel (2016-2021) & (K Units)
Table 99. Middle East and Africa Infectious Coryza Vaccine Sales by Distribution Channel (2022-2027) & (K Units)
Table 100. Middle East and Africa Infectious Coryza Vaccine Revenue by Distribution Channel (2016-2021) & (US$ Million)
Table 101. Middle East and Africa Infectious Coryza Vaccine Revenue by Distribution Channel (2022-2027) & (US$ Million)
Table 102. Middle East and Africa Infectious Coryza Vaccine Sales by Country (2016-2021) & (K Units)
Table 103. Middle East and Africa Infectious Coryza Vaccine Sales by Country (2022-2027) & (K Units)
Table 104. Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 105. Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 106. Zoetis Corporation Information
Table 107. Zoetis Description and Major Businesses
Table 108. Zoetis Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 109. Zoetis Infectious Coryza Vaccine Product
Table 110. Zoetis Recent Developments
Table 111. Merck Corporation Information
Table 112. Merck Description and Major Businesses
Table 113. Merck Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 114. Merck Infectious Coryza Vaccine Product
Table 115. Merck Recent Developments
Table 116. Boehringer Ingelheim Corporation Information
Table 117. Boehringer Ingelheim Description and Major Businesses
Table 118. Boehringer Ingelheim Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 119. Boehringer Ingelheim Infectious Coryza Vaccine Product
Table 120. Boehringer Ingelheim Recent Developments
Table 121. Ceva Santé Animale Corporation Information
Table 122. Ceva Santé Animale Description and Major Businesses
Table 123. Ceva Santé Animale Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 124. Ceva Santé Animale Infectious Coryza Vaccine Product
Table 125. Ceva Santé Animale Recent Developments
Table 126. Qilu Animal Health Products Co., Ltd. Corporation Information
Table 127. Qilu Animal Health Products Co., Ltd. Description and Major Businesses
Table 128. Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 129. Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product
Table 130. Qilu Animal Health Products Co., Ltd. Recent Developments
Table 131. Tianjin Ruipu Biotechnology Co., Ltd. Corporation Information
Table 132. Tianjin Ruipu Biotechnology Co., Ltd. Description and Major Businesses
Table 133. Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 134. Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product
Table 135. Tianjin Ruipu Biotechnology Co., Ltd. Recent Developments
Table 136. Harbin Pharmaceutical Group Corporation Information
Table 137. Harbin Pharmaceutical Group Description and Major Businesses
Table 138. Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 139. Harbin Pharmaceutical Group Infectious Coryza Vaccine Product
Table 140. Harbin Pharmaceutical Group Recent Developments
Table 141. Plyco Bioengineering Co., Ltd. Corporation Information
Table 142. Plyco Bioengineering Co., Ltd. Description and Major Businesses
Table 143. Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 144. Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product
Table 145. Plyco Bioengineering Co., Ltd. Recent Developments
Table 146. Qingdao Yibang Biological Engineering Co., Ltd. Corporation Information
Table 147. Qingdao Yibang Biological Engineering Co., Ltd. Description and Major Businesses
Table 148. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 149. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product
Table 150. Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments
Table 151. Shandong Lvdu Biological Technology Co., Ltd. Corporation Information
Table 152. Shandong Lvdu Biological Technology Co., Ltd. Description and Major Businesses
Table 153. Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 154. Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product
Table 155. Shandong Lvdu Biological Technology Co., Ltd. Recent Developments
Table 156. Shandong Huahong Biological Engineering Co., Ltd. Corporation Information
Table 157. Shandong Huahong Biological Engineering Co., Ltd. Description and Major Businesses
Table 158. Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 159. Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product
Table 160. Shandong Huahong Biological Engineering Co., Ltd. Recent Developments
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Infectious Coryza Vaccine Distributors List
Table 164. Infectious Coryza Vaccine Customers List
Table 165. Infectious Coryza Vaccine Market Trends
Table 166. Infectious Coryza Vaccine Market Drivers
Table 167. Infectious Coryza Vaccine Market Challenges
Table 168. Infectious Coryza Vaccine Market Restraints
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Infectious Coryza Vaccine Product Picture
Figure 2. Global Infectious Coryza Vaccine Market Share by Type in 2020 & 2027
Figure 3. Monovalent Vaccine Product Picture
Figure 4. Bivalent Vaccine Product Picture
Figure 5. Trivalent Vaccine Product Picture
Figure 6. Global Infectious Coryza Vaccine Market Share by Distribution Channel in 2020 & 2027
Figure 7. Retail
Figure 8. Online Sale
Figure 9. Others
Figure 10. Infectious Coryza Vaccine Report Years Considered
Figure 11. Global Infectious Coryza Vaccine Sales 2016-2027 (K Units)
Figure 12. Global Infectious Coryza Vaccine Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Infectious Coryza Vaccine Revenue 2016-2027 (US$ Million)
Figure 14. Global Infectious Coryza Vaccine Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 15. Global Infectious Coryza Vaccine Sales Market Share by Region (2016-2021)
Figure 16. Global Infectious Coryza Vaccine Sales Market Share by Region (2022-2027)
Figure 17. North America Infectious Coryza Vaccine Sales YoY (2016-2027) & (K Units)
Figure 18. North America Infectious Coryza Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Europe Infectious Coryza Vaccine Sales YoY (2016-2027) & (K Units)
Figure 20. Europe Infectious Coryza Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Asia-Pacific Infectious Coryza Vaccine Sales YoY (2016-2027) & (K Units)
Figure 22. Asia-Pacific Infectious Coryza Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Latin America Infectious Coryza Vaccine Sales YoY (2016-2027) & (K Units)
Figure 24. Latin America Infectious Coryza Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 25. Middle East & Africa Infectious Coryza Vaccine Sales YoY (2016-2027) & (K Units)
Figure 26. Middle East & Africa Infectious Coryza Vaccine Revenue YoY (2016-2027) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Infectious Coryza Vaccine Sales in 2020
Figure 28. The Top 10 and Top 5 Players Market Share by Infectious Coryza Vaccine Revenue in 2020
Figure 29. Infectious Coryza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 30. Global Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
Figure 31. Global Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
Figure 32. Global Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
Figure 33. Global Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
Figure 34. North America Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
Figure 35. North America Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
Figure 36. North America Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
Figure 37. North America Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
Figure 38. North America Infectious Coryza Vaccine Sales Share by Country (2016-2027)
Figure 39. North America Infectious Coryza Vaccine Revenue Share by Country (2016-2027)
Figure 40. United States Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 41. Canada Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 42. Europe Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
Figure 43. Europe Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
Figure 44. Europe Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
Figure 45. Europe Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
Figure 46. Europe Infectious Coryza Vaccine Sales Share by Country (2016-2027)
Figure 47. Europe Infectious Coryza Vaccine Revenue Share by Country (2016-2027)
Figure 48. Germany Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 49. France Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 50. U.K. Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 51. Italy Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 52. Russia Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 53. Asia Pacific Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
Figure 54. Asia Pacific Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
Figure 55. Asia Pacific Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
Figure 56. Asia Pacific Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
Figure 57. Asia Pacific Infectious Coryza Vaccine Sales Share by Region (2016-2027)
Figure 58. Asia Pacific Infectious Coryza Vaccine Revenue Share by Region (2016-2027)
Figure 59. China Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 60. Japan Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 61. South Korea Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 62. India Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 63. Australia Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 64. China Taiwan Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 65. Indonesia Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 66. Thailand Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 67. Malaysia Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 68. Latin America Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
Figure 69. Latin America Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
Figure 70. Latin America Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
Figure 71. Latin America Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
Figure 72. Latin America Infectious Coryza Vaccine Sales Share by Country (2016-2027)
Figure 73. Latin America Infectious Coryza Vaccine Revenue Share by Country (2016-2027)
Figure 74. Mexico Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 75. Brazil Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 76. Argentina Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 77. Middle East and Africa Infectious Coryza Vaccine Sales Market Share by Type (2016-2027)
Figure 78. Middle East and Africa Infectious Coryza Vaccine Revenue Market Share by Type (2016-2027)
Figure 79. Middle East and Africa Infectious Coryza Vaccine Sales Market Share by Distribution Channel (2016-2027)
Figure 80. Middle East and Africa Infectious Coryza Vaccine Revenue Market Share by Distribution Channel (2016-2027)
Figure 81. Middle East and Africa Infectious Coryza Vaccine Sales Share by Country (2016-2027)
Figure 82. Middle East and Africa Infectious Coryza Vaccine Revenue Share by Country (2016-2027)
Figure 83. Turkey Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 84. Saudi Arabia Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 85. UAE Infectious Coryza Vaccine Revenue (2016-2027) & (US$ Million)
Figure 86. Infectious Coryza Vaccine Value Chain
Figure 87. Infectious Coryza Vaccine Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed